Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “market perform” rating reissued by stock analysts at Leerink Swann in a research report issued to clients and investors on Saturday. They presently have a $120.00 price objective on the biopharmaceutical company’s stock. Leerink Swann’s price target points to a potential upside of 94.84% from the company’s current price.

A number of other analysts also recently weighed in on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Wells Fargo & Company reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a report on Monday, July 10th. They set a “buy” rating and a $275.00 price target for the company. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Finally, Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price target for the company in a report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Intercept Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $174.93.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded down 16.43% during mid-day trading on Friday, hitting $61.59. 11,875,646 shares of the company were exchanged. The company’s 50-day moving average price is $106.75 and its 200-day moving average price is $115.74. Intercept Pharmaceuticals has a 12-month low of $60.97 and a 12-month high of $172.95. The firm’s market capitalization is $1.55 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter in the prior year, the firm posted ($3.14) EPS. The firm’s quarterly revenue was up 459.6% on a year-over-year basis. Equities research analysts predict that Intercept Pharmaceuticals will post ($13.91) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals’ (ICPT) Market Perform Rating Reiterated at Leerink Swann” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/23/intercept-pharmaceuticals-icpt-market-perform-rating-reiterated-at-leerink-swann.html.

In other news, CMO David Shapiro sold 350 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.24, for a total transaction of $42,434.00. Following the completion of the sale, the chief marketing officer now directly owns 45,215 shares in the company, valued at $5,481,866.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Mark Pruzanski sold 40,000 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the sale, the chief executive officer now owns 611,718 shares of the company’s stock, valued at $80,012,714.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,013 shares of company stock valued at $6,198,747. Corporate insiders own 9.20% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ICPT. Teachers Advisors LLC increased its position in shares of Intercept Pharmaceuticals by 9.5% during the fourth quarter. Teachers Advisors LLC now owns 15,410 shares of the biopharmaceutical company’s stock worth $1,674,000 after buying an additional 1,339 shares during the period. US Bancorp DE acquired a new stake in shares of Intercept Pharmaceuticals during the first quarter worth $130,000. Bank of New York Mellon Corp increased its position in shares of Intercept Pharmaceuticals by 10.2% during the first quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock worth $7,725,000 after buying an additional 6,312 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Intercept Pharmaceuticals by 24.7% during the first quarter. BNP Paribas Arbitrage SA now owns 5,006 shares of the biopharmaceutical company’s stock worth $566,000 after buying an additional 990 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Intercept Pharmaceuticals by 14.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. Institutional investors own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.